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Effects of Vasodilation in Heart Failure
With Preserved or Reduced Ejection Fraction
Implications of Distinct Pathophysiologies on Response to Therapy
Shmuel Schwartzenberg, MD, Margaret M. Redfield, MD, Aaron M. From, MD, Paul Sorajja, MD,
Rick A. Nishimura, MD, Barry A. Borlaug, MD
Rochester, Minnesota
Objectives The purpose of this study was to compare hemodynamic responses to vasodilator therapy in patients with heart
failure (HF) and preserved ejection fraction (HFpEF) versus HF and reduced ejection fraction (HFrEF).
Background There is no proven therapy for HFpEF. In the absence of data, medicines with established benefit in HFrEF such
as vasodilators are frequently prescribed for HFpEF.
Methods We compared baseline hemodynamics and acute responses to vasodilation with intravenous sodium nitroprus-
side in patients with HFrEF (n  174) and HFpEF (n  83), determined invasively by cardiac catheterization.
Results Baseline blood pressure, stroke volume, and cardiac output were greater in HFpEF than HFrEF, while pulmonary artery
mean and pulmonary wedge pressures were similar. Left ventricular filling pressures were reduced to a similar extent
in each group with nitroprusside, but the drop in systemic arterial pressure was 2.6-fold greater in HFpEF (p 
0.0001), and improvements in stroke volume and cardiac output were each 60% lower in HFpEF compared to
HFrEF (p  0.0001). Despite similarly elevated filling pressures, HFpEF patients were fourfold more likely than HFrEF
to experience a reduction in stroke volume with nitroprusside (p  0.0001), suggesting greater vulnerability to pre-
load reduction. Pulmonary artery systolic pressure dropped more in HFpEF than in HFrEF despite similar reduction in
pulmonary mean pressure and resistance, suggesting higher right ventricular systolic elastance in HFpEF.
Conclusions As compared to patients with HFrEF, patients with HFpEF experience greater blood pressure reduction, less en-
hancement in cardiac output, and greater likelihood of stroke volume drop with vasodilators. These findings
emphasize fundamental differences in the 2 HF phenotypes and suggest that more pathophysiologically
targeted therapies are needed for HFpEF. (J Am Coll Cardiol 2012;59:442–51) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.062d
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sApproximately one-half of patients with heart failure (HF)
have preserved ejection fraction (HFpEF) and the remainder
have heart failure with reduced ejection fraction (HFrEF) (1).
linical presentation is similar in both forms of HF, and
ecause abnormalities in ventricular and vascular function are
ommon to each, it has been proposed that HFpEF and
FrEF are part of the same “HF continuum” (2). However,
herapies with unequivocal benefit in HFrEF have failed to
how efficacy in HFpEF (3–5), suggesting important patho-
hysiologic differences. In the absence of proven treatments for
FpEF, it is important to understand potential differences in
esponse to empiric HF therapies, and appreciation of unique
athophysiology in the 2 types of HF may better inform
election of interventions to be tested in future trials.
From the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic
Rochester, Rochester, Minnesota. The authors have reported they have no relation-
ships relevant to the contents of this paper to disclose.Manuscript received June 10, 2011; revised manuscript received August 22, 2011,
accepted September 20, 2011.Vasodilators are a cornerstone in the management of both
ecompensated and chronic HFrEF (3–7). Favorable acute
emodynamic effects of vasodilation in HFrEF are due in
arge part to enhanced afterload sensitivity of the dilated,
ailing ventricle (7–9). Although systolic function is not com-
letely normal in HFpEF, both systolic and diastolic ventric-
lar vascular stiffness are typically elevated (10,11), Theoretical
nd clinical data from small studies suggest that this combined
entricular-arterial stiffening may promote exaggerated blood
ressure response to changes in ventricular loading in HFpEF,
ncluding hypertensive crisis with vasoconstriction, or hypoten-
ion with overly aggressive vasodilation (10,12).
See page 452
We sought to compare the acute hemodynamic effects of
vasodilation with nitroprusside in patients with HFpEF
and HFrEF. We hypothesized that hemodynamic changes
with vasodilation are fundamentally different in the 2 HF
populations—with greater systemic arterial pressure drop and
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January 31, 2012:442–51 Vasodilation in HFpEF and HFrEFless augmentation of stroke volume in HFpEF as compared to
HFrEF.
Methods
Study population. We examined consecutive patients with
F referred to the Mayo Clinic cardiac catheterization
aboratory between October 2002 and July 2009 for right
eart catheterization (with or without left heart catheteriza-
ion) who underwent acute vasodilator challenge with intrave-
ous sodium nitroprusside. Nitroprusside is routinely admin-
stered in our laboratory when pulmonary wedge pressure is
levated to assess reversibility. Patients with primary left-sided
alvular heart disease, cardiac transplantation, on inotrope or
ressor therapy, with complex congenital disease or shock were
xcluded. The study was approved by the Mayo Clinic insti-
utional review board.
atheterization protocol. Patients were studied receiving
hronic medications in the fasted state after minimal seda-
ion in the supine position. Standard right heart catheter-
zation was performed through the internal jugular or
emoral vein. Left heart catheterization was performed by
he retrograde transaortic approach from the radial or
emoral artery, as described previously (13), in a subset of
atients (n  89). All measurements were performed at
nd-expiration off line by 1 investigator (S.S.) from elec-
ronically stored continuous recordings of pressure tracings.
ystemic arterial blood pressure (BP) was measured inva-
ively (n  217) or by cuff sphygmomanometry
n  40). Cardiac output was determined by the Fick
ethod or by thermodilution. Stroke volume (SV) was
etermined by cardiac output divided by heart rate.
itroprusside infusion. After baseline hemodynamic data
ere acquired, sodium nitroprusside was administered at
ncremental doses starting at 0.25 to 0.5 g/kg/min, titrated
to: 1) normalization in pulmonary wedge pressure; 2) reduction
in systolic BP to 90 mm Hg; or 3) patient intolerance (e.g.,
lightheadedness). Hemodynamic measurements were then
repeated.
Case definitions. Clinical data were obtained from de-
tailed chart review. Echocardiographic data was abstracted
from clinically obtained studies performed before catheter-
ization. HFpEF was defined by cardiologist adjudicated HF
diagnosis (Framingham criteria), EF 50%, the absence of
ignificant valvular disease (more than moderate left-sided
egurgitation or any stenosis), and after exclusion of patients
ith constrictive pericarditis, and infiltrative, restrictive, or
ypertrophic cardiomyopathies. HFrEF was defined em-
loying the same criteria, with EF 50%. Patients with
FrEF and functional mitral regurgitation were not ex-
luded, provided that primary mitral valve pathology was
bsent.
emodynamic definitions. LV end-systolic and end-
iastolic volumes were determined from the Teicholz
ethod based upon echocardiography. Left ventricular pre-oad was defined by end-diastolic volume (12). LV end- (ystolic volume changes during
itroprusside infusion were esti-
ated by the difference in echo-
ardiographic end-diastolic volume
nd directly measured SV. LV end-
ystolic pressure was taken as
.9*systolic BP. The LV end-
ystolic elastance (Ees) was esti-
ated by the ratio of end-systolic
ressure to end-systolic volume. Sys-
emic arterial afterload was as-
essed by effective arterial elas-
ance (Ea), defined as the ratio of
nd-systolic pressure to SV (12).
entricular-arterial coupling was
ssessed by the ratio of Ea/Ees
12). Pulsatile load, referring to
he nonresistive, oscillatory components of arterial afterload,
as assessed by systemic arterial pulse pressure and compli-
nce (SV divided by pulse pressure) (14). Pulmonary vas-
ular resistance was determined using standard formula
13).
tatistical analysis. Data are reported as mean  SD or
edian (25th, 75th interquartile range). Between-group
ifferences were compared by t test, Wilcoxon rank-sum
est, or chi-square. Bivariate regression (Pearson coefficient)
as used to examine correlations between continuous mea-
ures. Multivariable linear regression analysis was used to
djust for relevant baseline group differences, in which the
ependent variable was the normally distributed continuous or
ategorical outcome variable of interest, and factors entered
nto the model included age, sex, body mass, group (dummy
ariable), and relevant interaction terms. For non-normally
istributed variables entered into regression models, the as-
umption of normally distributed residuals was verified by
uantile plots, and no major violations were observed.
esults
ubject characteristics. Between October 2002 and July
009, 449 patients received nitroprusside infusion during
nvasive hemodynamic study. From this population, 174
atients were identified with HFrEF and 83 with HFpEF.
Diagnoses for excluded patients are provided in the Online
ppendix.) Patients with HFpEF were older, more likely to
e female and hypertensive, and had larger body mass index
ompared with HFrEF (Table 1). Patients with HFrEF
ere more likely to be treated with beta-blockers, digoxin,
nd inhibitors of the angiotensin-aldosterone axis, and less
ikely to be treated with calcium-channel blockers compared
ith HFpEF patients. Most patients were receiving diuret-
cs. Natriuretic peptide and serum hemoglobin levels were
igher in HFrEF patients. Cardiomegaly on chest film was
ore common in HFrEF patients.
Echocardiography was performed a median of 6 days
Abbreviations
and Acronyms
BP  blood pressure
Ea  effective arterial
elastance
Ees  end-systolic
elastance
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HFrEF  heart failure with
reduced ejection fraction
LV  left ventricular
RV  right ventricle
SV  stroke volumeinterquartile range: 2 to 28 days) before catheterization,
ejectio
RV  r
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Vasodilation in HFpEF and HFrEF January 31, 2012:442–51with no difference between groups in the interval (p 
0.60). LV chamber dimension, mass, volumes, and left atrial
size were greater in HFrEF, whereas wall thickness and the
ratio of wall thickness to chamber volume were higher in
HFpEF (Table 1). Patients with HFrEF more commonly
displayed qualitative right ventricular systolic dysfunction
and had more severe LV diastolic dysfunction based upon
Doppler echocardiography, compared with HFpEF.
Baseline hemodynamics. At rest, right atrial, mean pul-
monary artery, and pulmonary wedge pressures were similar
in HFpEF and HFrEF, although LV end-diastolic pres-
Baseline CharacteristicsTable 1 Baseline Characteristics
HFrEF
Age, yrs 56
Female
Body mass index, kg/m2 29.5
Body surface area, m2 2.07
Comorbidities
Hypertension
Diabetes mellitus
Coronary disease
COPD
Medications
Beta-blockers
ACEI or ARB
Diuretics
Aldosterone antagonists
Digoxin
Calcium antagonists
Laboratory values
Sodium, mmol/l 139 (1
Hemoglobin, g/dl 13.0
GFR, ml/min/1.73 m2 65 (4
NT-proBNP, pg/ml 3,913 (2
BNP, pg/ml 751 (3
Cardiomegaly on chest film
Echocardiography
LV septum, mm 10 (9
LV diastolic dimension, mm 68
LV end-diastolic volume, ml 246
LV mass, g 311
LV mass/end-diastolic volume 1.32
Left atrial volume, ml/m2 58
LV ejection fraction, % 22
Grade 3 or 4 mitral regurgitation, %
Severe tricuspid regurgitation, %
E/A ratio 2.5 (1
Tissue Doppler E’, cm/s 4.0 (3
E/e’ ratio 22 (1
Deceleration time, ms 139
RV dysfunction,* %
Values are mean  SD, %, or median (25th to 75th interquartile ra
abstracted from the clinical records.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiote
obstructive pulmonary disease; E/A  transmitral early to late filling
GFR  glomerular filtration rate; HFpEF  heart failure with preserved
left ventricular; NT-proBNP  N-terminal pro-brain natriuretic peptide;sures were somewhat higher in HFrEF (Table 2). Patientswith HFpEF had higher BP, pulmonary artery systolic
pressure, cardiac output, and SV compared with HFrEF,
while heart rate and pulmonary vascular resistance were
similar in both groups. Pulmonary artery saturations were
lower in HFrEF compared with HFpEF, yet 75% of
HFpEF patients displayed saturations below the normal
range (68%), consistent with inadequate perfusion relative
to metabolic needs.
The pulsatile contribution to systemic arterial pressure
was greater in HFpEF, evidenced by higher pulse pressure,
lower arterial compliance, and greater systolic BP for any
174) HFpEF (n  83) p Value
69 9 0.0001
71 0.0001
33.2 8.3 0.0001
5 2.05 0.30 0.60
66 0.02
45 0.90
61 0.40
18 0.90
78 0.002
76 0.02
89 0.10
16 0.0001
20 0.0001
41 0.0001
1) 141 (138–142) 0.0001
12.1 1.7 0.001
57 (47–69) 0.10
8,160) 1,360 (781–3,716) 0.002
520) 371 (206–597) 0.0001
56 0.01
10 (10–12) 0.0001
48 5 0.0001
108 28 0.0001
5 198 56 0.0001
8 1.91 0.57 0.0001
49 22 0.0001
63 6 0.0001
0 0.0001
15 0.50
) 1.3 (1.1–2.1) 0.0001
) 6.0 (4.0–7.0) 0.0001
18 (14–27) 0.007
179 39 0.0001
18 0.0001
Refers to qualitative impression based upon echocardiography, as
eptor blocker; BNP  brain natriuretic peptide; COPD  chronic
ratio; E/e’  early diastolic transmitral flow to tissue velocity ratio;
n fraction; HFrEF  heart failure with reduced ejection fraction; LV 
ight ventricular.(n 
 12
25
 5.8
 0.2
48
44
69
17
90
88
95
48
58
8
37–14
 1.9
5–80)
,177–
52–1,
73
–11)
 11
 90
 10
 0.3
 19
 9
27
19
.7–3.3
.0–5.0
7–32)
 34
54
nge). *
nsin-rec
velocityarterial elastance (Ea) (Fig. 1). Ventricular-arterial coupling
ntricula
stroke
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January 31, 2012:442–51 Vasodilation in HFpEF and HFrEFwas more deranged in HFrEF: LV Ees was nearly an order
of magnitude lower compared with HFpEF (Table 2),
whereas baseline Ea was somewhat higher in HFpEF. The
coupling ratio (Ea/Ees) was fivefold higher in HFrEF
compared with HFpEF, consistent with afterload mis-
Baseline HemodynamicsTable 2 Baseline Hemodynamics
HFrEF (
Peripheral hemodynamics
Heart rate, beats/min 70 (62
Systolic BP, mm Hg 113 (10
Mean BP, mm Hg 80 (74
Systemic arterial saturation, % 93 (90
Central hemodynamics
Right atrial pressure, mm Hg 14
Mean PA pressure, mm Hg 40
PA systolic pressure, mm Hg 59
PCWP, mm Hg 25
LV end-diastolic pressure, mm Hg 26
Flow and resistance data
Cardiac output, l/min 4.0 (3.
SV, ml 58 (44
Pulmonary artery saturation, % 55 (50
PVR, Woods units 3.3 (2.
Arterial-ventricular coupling
Ees, mm Hg/ml 0.54 (0.
Ea, mm Hg/ml 1.7 (1.
Coupling ratio, Ea/Ees 3.3 (2.
Values are mean  SD or median (25th to 75th interquartile range).
BP blood pressure; Ea effective arterial elastance; Ees left ve
capillary wedge pressure; PVR  pulmonary vascular resistance; SV 
Figure 1 Pulsatile Arterial Loading in HFpEF and HFrEF
Pulsatile afterload was greater in heart failure with preserved ejection fraction (HF
with higher pulse pressure, lower arterial compliance, and higher systolic arterial p
and ‡interaction term comparisons. BP  blood pressure.match. All group differences persisted after adjusting for
age, sex, and body mass index.
Hemodynamic responses with nitroprusside. There was
no difference in nitroprusside dose administered between
the groups (Table 3). Cardiac output was remeasured during
4) HFpEF (n  83) p Value
70 (60–76) 0.20
7) 166 (144–180) 0.0001
104 (93–118) 0.0001
94 (90–96) 0.80
14 6 0.80
41 10 0.50
64 18 0.02
22 6 0.30
22 6 0.008
4.7 (4.1–6.0) 0.0001
73 (56–85) 0.0001
61 (57–67) 0.0001
3.3 (2.0–5.0) 0.80
5) 3.7 (3.0–4.7) 0.0001
2.0 (1.6–2.8) 0.03
0.58 (0.40–0.72) 0.0001
r end-systolic elastance; PA pulmonary artery; PCWP pulmonary
volume; other abbreviations as in Table 1.
lack) compared with heart failure with reduced ejection fraction (HFrEF) (red),
re for a given arterial elastance. The p values are shown for bivariate, †group,n  17
–81)
0–12
–92)
–96)
 6
 9
 14
 6
 6
4–4.8)
–71)
–62)
4–4.6)
40–0.8
5–2.4)
1–4.8)pEF) (b
ressu
C
p
E
s
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Vasodilation in HFpEF and HFrEF January 31, 2012:442–51nitroprusside in 157 HFrEF patients and 51 HFpEF
patients, and all subjects had paired measures of pressure
data. There were no differences in baseline characteristics
between patients who did and did not have cardiac output
remeasured during nitroprusside (Online Appendix). De-
spite similar reductions in systemic afterload (Ea) with
nitroprusside in both groups, patients with HFpEF experi-
enced 2.5- and 1.7-fold greater drops in systolic and
mean arterial BP compared with HFrEF (Fig. 2, Table 3).
Hemodynamic Changes With NitroprussideTable 3 Hemodynamic Changes With Nitrop
HFrEF (
Nitroprusside dose, g/kg/min 1.5 (1–3
Peripheral changes
 Heart rate, beats/min 2
 Systolic BP, mm Hg 22 (1
 Mean BP, mm Hg 18 (1
Central changes
 Mean PA pressure, mm Hg 12
 PA systolic pressure, mm Hg 15
 PCWP, mm Hg 9
 LV end-diastolic pressure, mm Hg 8
Flow and resistance changes
 Cardiac output, l/min 1.9
 SV, ml 23
 PVR, Woods units 1.4 (0
 Ea, mm Hg/ml 0.8 (0
Values are mean  SD or median (25th to 75th interquartile range).
Abbreviations as in Tables 1 and 2.
Figure 2 Peripheral and Central Hemodynamic Changes With N
Nitroprusside caused greater blood pressure (BP) reduction in heart failure with pr
ejection fraction (HFrEF) (red), whereas augmentation in stroke volume (SV) and c
wedge pressure; SBP  systolic blood pressure.Conversely, patients with HFrEF displayed twofold to
3-fold greater increases in SV and cardiac output compared
with HFpEF. The proportional increase in SV (relative to
baseline) with nitroprusside was fourfold greater in HFrEF
than HFpEF (49  50% vs. 13  31%, p  0.0001).
hanges in heart rate and LV filling pressures with nitro-
russide were similar in HFrEF and HFpEF (Fig. 2, Table 3).
ach of these differences persisted after adjusting for age,
ex, body mass index, and nitroprusside dose.
de
74) HFpEF (n  83) p Value
2 (1–2) 0.50
4 9 0.15
36) 51 (28 to71) 0.0001
27) 30 (19 to42) 0.0001
11 8 0.70
19 13 0.02
9 6 0.70
9 6 0.90
0.8 1.4 0.0001
8 21 0.0001
2.4) 1.1 (0.1 to2.0) 0.09
1.3) 0.6 (0.5 to1.2) 0.40
russide
d ejection fraction (HFpEF) (black) compared with heart failure with reduced
output were greater in HFrEF compared with HFpEF. PCWP  pulmonary capillaryrussi
n  1
)
 9
1 to
0 to
 8
 11
 6
 5
 1.4
 20
.7 to
.4 toitrop
eserve
ardiac
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i
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January 31, 2012:442–51 Vasodilation in HFpEF and HFrEFThe HFrEF patients with significant (grade 3 to 4) mitral
regurgitation tended to show greater hemodynamic im-
provements compared to HFrEF patients without mitral
regurgitation, but after restricting the analysis to HFrEF
without significant mitral regurgitation, each of the
HFpEF-HFrEF group comparisons remained highly sig-
nificant (Online Appendix). Group differences in stroke
volume, cardiac output, and blood pressure persisted after
recategorizing HFpEF as patients with EF 45% and
EF 40%.
Figure 3A shows the distributions of SV change with
itroprusside in HFrEF and HFpEF. Despite the predom-
nant arterial vasodilator properties of nitroprusside (6) and
the presence of elevated LV filling pressures, SV actually
decreased in 35% of HFpEF patients with nitroprusside,
compared with only 9% of HFrEF patients (p  0.0001).
ubgroup analysis revealed that baseline pulmonary capillary
edge pressure was lower and the increase in heart rate
reater with nitroprusside among patients with a drop in SV
ompared to patients with enhanced SV, but LV filling
ressures were elevated in both groups (Online Appendix).
mportantly, observed disparities in BP, SV, and cardiac
utput response to nitroprusside in HFpEF and HFrEF
Figure 3 Pressure-Flow Changes With Load Alteration
(A) Cumulative distribution plot shows attenuated enhancement in stroke volum
with heart failure with reduced ejection fraction (HFrEF) (red), as 35% of HFpEF
(p  0.0001) (dashed lines). (B) Drop in systemic arterial blood pressure (B
pared with HFrEF. (C) Increase in SV as a function of left ventricular filling pres
systolic pressure (PASP) with vasodilation was greater in HFpEF compared to H
comparisons. See text for details.persisted after excluding patients with SV reduction or with
baseline pulmonary wedge pressures below 20 or 25 mm Hg
(Online Appendix).
Determinants of the nitroprusside response. The reduc-
tion in BP with nitroprusside correlated with the decrease in
arterial afterload (Ea) in all patients (p  0.0001), but for
any drop in Ea, the reduction in systolic BP was steeper in
HFpEF compared with HFrEF (group p  0.0001; inter-
action term p  0.003) (Fig. 3B). These differences
persisted after adjusting for age, sex, and body mass
index. Changes in pulmonary wedge pressure with nitro-
prusside were not related to changes in BP, SV, heart
rate, cardiac output, or Ea. Enhancement in SV as a
function of LV filling pressure was greater in HFrEF
than HFpEF (Fig. 3C).
Changes in LV end-systolic pressure and estimated
end-systolic volume with nitroprusside are displayed graph-
ically in Figure 4, plotting median baseline Ees estimates
(solid lines), end-diastolic volumes from echocardiography,
and observed reductions in Ea (dashed lines). Assuming
that Ees and end-diastolic volume did not change on
average with nitroprusside, observed changes in end-systolic
pressure-volume coordinates (diamonds) fall very close to
) in heart failure with preserved ejection fraction (HFpEF) (black) compared
nts displayed a reduction in SV with nitroprusside compared with 9% of HFrEF
accentuated for any degree of vasodilation (Ea reduction) in HFpEF com-
with nitroprusside was greater in HFrEF. (D) Reduction in pulmonary artery
The p values in B and D reflect bivariate, †group, and ‡interaction terme (SV
patie
P) was
sure
FrEF.
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Vasodilation in HFpEF and HFrEF January 31, 2012:442–51values predicted by the estimated baseline end systolic
pressure-volume relationships (Fig. 4).
Right-sided ventricular-arterial coupling. Despite similar
mean pressures, pulmonary artery systolic pressure was
higher in HFpEF than in HFrEF (Table 2), even after
adjusting for pulmonary wedge pressure, pulmonary vascular
resistance, and SV. With nitroprusside, pulmonary artery
systolic pressure decreased more in HFpEF than in HFrEF
despite similar changes in pulmonary wedge pressure and
pulmonary arteriolar resistance (Table 3). After adjusting
for changes in pulmonary wedge pressure and pulmonary
vascular resistance, the drop in pulmonary arterial systolic
pressure was greater in HFpEF than in HFrEF (Fig. 3D),
suggesting higher right ventricular Ees in HFpEF and
greater right ventricular afterload mismatch in HFrEF.
Discussion
We compared hemodynamics at rest and during nitroprus-
side infusion in a large cohort of well-characterized patients
with HF and preserved or reduced ejection fraction. In the
left-sided circulation, we observed greater pulsatile arterial
loading in HFpEF and greater LV-arterial mismatch in
HFrEF, as previously demonstrated. We show that these
alterations in ventricular-arterial properties in HFpEF and
HFrEF are associated with fundamental differences in the
response to vasodilation. Patients with HFpEF had more
exaggerated drops in BP and less enhancement in SV and
cardiac output compared with HFrEF. LV filling pressures
were similarly elevated in patients with HFrEF and HFpEF
at baseline. With nitroprusside, filling pressures dropped to
similar extent in both forms of HF, yet patients with
Figure 4 Observed and Predicted End-Systolic
Pressure-Volume Changes With Nitroprusside
Observed changes in estimated end-systolic pressure-volume coordinates
(diamonds) in heart failure with preserved ejection fraction (HFpEF) (black)
compared with heart failure with reduced ejection fraction (HFrEF) (red) with
reduction in arterial elastance (Ea) (dashed lines) were very similar to
those predicted based on resting left ventricular end-systolic elastance
(Ees) (straight lines) and the observed changes in Ea. See text for details.HFpEF were more likely to experience a reduction in SV,suggesting greater vulnerability to venodilator effects and
excessive drop in preload. In the right ventricular-
pulmonary arterial circulation, we also observed more
exaggerated drops in systolic arterial pressure despite
similar reduction in pulmonary venous pressures. These
findings emphasize important mechanistic differences in
the 2 distinct HF phenotypes and raise questions regard-
ing the empiric use of vasodilator-based treatment ap-
proaches in the absence of established indications in
patients with HFpEF.
Surprisingly few studies have compared hemodynamics in
HFpEF and HFrEF, and none have contrasted responses to
clinical intervention. van Heerebeek et al. (15) examined LV
properties in 22 patients with HFpEF and 22 patients with
HFrEF. As in the current study, LV filling pressures at rest
were similarly elevated in HFpEF and HFrEF, leading the
authors to suggest that hemodynamics alone do not distin-
guish these HF phenotypes. Although the current data
confirm similarities in filling pressures at baseline, they
highlight important, fundamental differences in arterial
pressure and flow responses with vasodilation in HFpEF
and HFrEF in both the left- and right-sided circulations.
These findings may have important implications for the care
of patients with HFpEF.
Ventricular-arterial interaction in HF. Changes in BP
and SV with alteration in ventricular loading conditions are
predictable based upon concepts of ventricular-arterial cou-
pling (8,9,12,16). BP decreases while the SV increases with
vasodilation, and the extent of change in each is dictated by
slope and intercept of the end-systolic pressure volume
relationship, termed end-systolic elastance (Ees) (Fig. 4).
While elevated arterial afterload (Ea) is common to both
forms of HF, the 2 entities differ dramatically in the “active”
stiffness (contractility) developed by the heart at end systole,
or Ees (8,17). In HFpEF, Ees is elevated (10), despite mild
abnormalities in myocardial and chamber contractility (11),
likely because passive components of stiffness are elevated
(15). In an elegant study, Kawaguchi et al. (10) demon-
strated that elevated Ees in HFpEF leads to an exaggerated
hypertensive response to isometric handgrip, providing
mechanistic insight into to the hypertensive pulmonary
edema commonly observed in these patients (18). We show
for the first time in a large series of HFpEF patients the
converse is also true: with acute decreases in afterload, there
are also more dramatic drops in BP. The average changes in
pressure and volume were strikingly similar to those pre-
dicted based upon median estimated end-systolic pressure-
volume relationships in HFpEF patients (Fig. 4).
In contrast, the shallow end-systolic pressure volume
relationship in HFrEF (low Ees) (Fig. 4) predicts the
opposite: lesser drop in BP and higher gain in SV with Ea
reduction. This phenomenon allows HFrEF patients to
tolerate very high doses of vasodilators without hemody-
namic embarrassment, as previously described (6–8). In
healthy humans, Ees and Ea are closely matched to opti-
mize stroke work and efficiency, with Ea/Ees ratios of 0.5 to
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tractility (Ees) is depressed, creating afterload mismatch,
such that the failing heart is operating farther from optimal
efficiency (16,17). Enhanced coupling in HFrEF is best
achieved pharmacologically through vasodilation rather
than augmentation of Ees, because of the increased myo-
cardial oxygen demand and toxicity associated with ino-
tropes (12).
In the HFpEF subjects in this study and previous reports
(10), Ea/Ees was 0.5 at baseline, indicating that the
ventricular-arterial system was already operating at near
maximum efficiency (9,16). Therefore, there was less to be
gained from vasodilation from a mechanical pump perspec-
tive. This observation, combined with the potentially
greater risk of hypotension or depression of SV, suggests
that vasodilator-based approaches may not be as broadly
applicable to HFpEF as they are to HFrEF. An important
exception is the HFpEF patient with uncontrolled hyper-
tension or hypertensive pulmonary edema, wherein vasodi-
lator therapy is very effective to control BP and relieve
symptoms of HF (18).
In addition to ventricular stiffening, vascular stiffening
contributes to BP lability with load alteration in HFpEF
(10,12,19). We observed that the pulsatile components of
arterial afterload were greater in HFpEF as compared with
HFrEF (Fig. 1), confirming and extending upon prior
noninvasive studies (20). The drop in arterial pressure with
Ea reduction was steeper in HFpEF compared with HFrEF
(Fig. 3B), indicating a higher afterload dependency of BP in
HFpEF. Enhanced pressure sensitivity with load alteration
is known to be present in normal aging (19), and similar to
epidemiologic studies (20), HFpEF patients were older than
HFrEF patients in the current study. However, each of the
observed differences in pressure and flow responses with
nitroprusside persisted after adjusting for age, sex, and body
size.
Diastolic responses to vasodilation in HF. Despite
marked peripheral hemodynamic differences with nitroprus-
side, central cardiac pressures dropped to a similar extent on
average in HFpEF and HFrEF, though HFpEF patients
were more likely to experience a drop in SV. Afterload
elevation prolongs diastolic relaxation (21), and it is thought
that vasodilation may correspondingly enhance diastolic
function (14,22). Somewhat surprisingly, there was no
relationship between the change in BP or Ea and the extent
of reduction in filling pressures, suggesting a less direct role
for afterload-mediated effects on diastolic function in this
study.
Nitroprusside is considered to be predominantly an arterial
vasodilator (6), although venodilator effects play an important
ole in reducing LV filling pressures (7). In the current study,
the drop in Ea was similar in both groups, but HFpEF patients
were more likely to have a reduction in SV, and the enhance-
ment in SV as a function of LV filling pressures was lower in
HFpEF than HFrEF (Figs. 3A and 3C). Because LV end-
systolic volume is unlikely to increase with afterload reduction,the drop in SV with nitroprusside by default was almost
certainly due to a decrease in LV end-diastolic volume (pre-
load). SV reduction with nitroprusside was observed in 35% of
HFpEF patients compared with only 9% of HFrEF patients,
despite the presence of elevated filling pressures in both groups.
This finding suggests that HFpEF patients were more likely to
be operating closer to the “shoulder” of their Starling curves,
where further reduction in filling pressure limits SV and stroke
work. That could make HFpEF patients more vulnerable to
deleterious effects of vasodilation.
Reduction in LV filling pressure with nitrates are com-
plex and may be due to improvement in afterload-
dependent relaxation delay, decrease in chamber volume
from venodilation, acute improvement in diastolic compli-
ance, or relief of pericardial constraint (6,7,23–25). Absent
volume data obtained at the time of catheterization, we
cannot determine the relative roles these mechanisms played
in the current study.
Right-sided circulation. Given the lower operating pres-
sures in the pulmonary circulation, the right ventricle (RV)
is poorly adapted to pressure overload, and similar to the LV
in HFrEF, the RV is exquisitely sensitive to acute changes
in afterload (26). Indeed, the presence of pulmonary hyper-
tension is a potent predictor of mortality in HFrEF and
HFpEF (27,28), and pulmonary vasodilators are being
tested in both forms of HF. Chronic elevation in left-sided
filling pressures raises pulmonary pressure and can lead to
secondary pulmonary arterial hypertension and right-side
heart failure (27), yet it is unknown whether this progres-
sion affects patients with HFrEF and HFpEF differently. In
the current study, patients with HFrEF were more likely to
display RV systolic dysfunction by echocardiography, de-
spite similar mean pulmonary artery pressure and resistance.
The drop in pulmonary artery systolic pressure with vaso-
dilation was attenuated in HFrEF compared with HFpEF
(Fig. 3D), suggesting that RV Ees is also greater in HFpEF
compared with HFrEF on average, although the disparities
in response to vasodilation were less dramatic than those
observed in the systemic circulation.
Implications for treatment. Vasodilators targeting the
renin-angiotensin system produce unequivocal benefit in
HFrEF, related to both vasorelaxation properties and block-
ade of maladaptive neurohormonal signaling, yet several
large clinical trials have failed to demonstrate similar benefit
in HFpEF (3–5). The diverging hemodynamic responses
noted in the current study may explain part of this disparity,
while allowing clinicians to better anticipate effects of
vasodilators in the individual HF patient. For example,
excessive reduction in BP or SV with vasodilation in
HFpEF could potentially offset any benefit from antago-
nism of pathologic neurohormonal activation, particularly
among the elderly where orthostatic tolerance and vascular
stiffening are more problematic (19). Despite the negative
trials, vasodilators are sometimes prescribed for HFpEF in
the absence of other compelling indications on the basis of
their established efficacy for HFrEF. The current findings
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with HFpEF and uncontrolled hypertension may benefit
from vasodilators.
Study limitations. This study is limited by its retrospective
nature, cross-sectional design, and catheterization labora-
tory referral population. The sample is limited to patients
who received nitroprusside, suggesting possible bias, al-
though in our laboratory it is routine to administer nitro-
prusside to all patients in whom left heart filling pressures
are elevated, regardless of EF. Echocardiography was per-
formed before catheterization, and simultaneous volumetric
data were not available, limiting direct measurements of
pressure volume relationships. LV Ees was estimated using
non-simultaneous echocardiographic volume data and as-
suming zero volume intercept in all patients, with no change
in end-diastolic volume or parallel shift in Ees with nitro-
prusside (Fig. 4). On the basis of prior studies, it is likely
that these assumptions were frequently violated (7,9,29).
However, the goal of the study was simply to determine
whether the central and peripheral hemodynamic re-
sponses categorically differ in HFpEF and HFrEF, and
these exploratory analyses were conducted to examine the
possible hemodynamic underpinnings for the observed
differences. The HFpEF group studied was hypertensive
(median systolic BP 166 mm Hg), and these results may
not apply to patients with better BP control. Cardiac
output was not assessed during nitroprusside in all cases,
although pressure data were available for all, and charac-
teristics of patients with and without output reassessment
were similar.
Conclusions
Although HFpEF and HFrEF share many similarities in
terms of clinical presentation and outcomes, important
differences exist in pathophysiology and response to therapy.
Whereas hemodynamic abnormalities at rest are similar in
HFpEF and HFrEF, the 2 HF phenotypes display mark-
edly different responses to vasodilation related to fundamen-
tal, disease-specific differences ventricular-arterial proper-
ties—with greater BP reduction in HFpEF and more SV
enhancement in HFrEF. These data provide further evi-
dence justifying the distinction of HFpEF and HFrEF as
separate HF phenotypes, and they suggest that alternative
treatment strategies targeted to ventricular-vascular stiffen-
ing rather than afterload reduction may have greater likeli-
hood of benefit in HFpEF.
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